Abstract
The future of mammalian cell culture is bright; thus, it is expanding. Many challenges remain, and new opportunities will emerge. This chapter reviews current breakthroughs in biopharmaceutical manufacturing utilizing mammalian cell culture, with a focus on monoclonal antibodies (MAbs), which are the biopharmaceutical industry’s most dominating and rapidly increasing sector, with large-scale production being the most established. The biotechnological elements of mammalian cell culture have received the most attention in this study. Mammalian cell culture has advanced from its foundation in the nineteenth century to serve as a platform for the formulation of viral vaccines, monoclonal antibodies, and other recombinant proteins, which is in much demand in recent era. Plenty more biopharmaceuticals derived from mammalian cell culture will be accessible as we move to the next century. The goal of this chapter is to expose the reader to the science and technology of in vitro mammalian cell culture as well as to demonstrate the influence of cell line developments in human health and well-being. This analysis is on the biotechnology of cell culture, which includes use of certain mammalian cells to manufacture goods or the cultivation of cells as commodities in their own terms. Mammalian cell culturing is the leading expression system for the production of biologics, owing to their potential of post-translational modification which is indispensable drug safety and efficacy. With the several enhancements in volumetric and specific productivities, the biologics production using mammalian cell culture has grown substantially, in last few years. This chapter presents an overview of biologics market, basics of equipment, and various types of bioreactors used for their production, as well as various techniques designed for improved protein expression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aggarwal SR (2012) What’s fueling the biotech engine—2011 to 2012. Nat Biotechnol 30(12):1191–1197
Arora M (2015) Cell culture media: a review. University of Pittsburgh Medical Center United States. https://doi.org/10.13070/mm.en.3.175.2015-08-02.
Bartczak M, Wierzchowski K, Pilarek M (2022) Mixing performance in a litre-scale rocking disposable bioreactor: DoE-based investigation of mixing time dependence on operational parameters. Chem Eng J 431:133288
Bhatia S (2015) Plant tissue culture. In: Modern applications of plant biotechnology in pharmaceutical sciences, pp 31–107
Bielser JM, Wolf M, Souquet J, Broly H, Morbidelli M (2018) Perfusion mammalian cell culture for recombinant protein manufacturing—A critical review. Biotechnol Adv 36(4):1328–1340
Chambers SA, Isenberg D (2005) Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14(3):210–214
Chin CL, Chin HK, Chin CSH, Lai ET, Ng SK (2015) Engineering selection stringency on expression vector for the production of recombinant human alpha1-antitrypsin using Chinese Hamster ovary cells. BMC Biotechnol 15(1):1–15
De Bartolo L (2016) Hollow fiber membrane bioreactor for cell growth. In: Drioli E, Giorno L (eds) Encyclopedia of membranes. Springer, Berlin. https://doi.org/10.1007/978-3-662-44324-8_1191
De Poorter JJ, Lipinski KS, Nelissen RG, Huizinga TW, Hoeben RC (2007) Optimization of short-term transgene expression by sodium butyrate and ubiquitous chromatin opening elements (UCOEs). J Gene Med 9(8):639–648
The biopharmaceuticals contract manufacturing market to witness tremendous growth with a CAGR of 7.38% during the study period (2019–2027), DelveInsight, 2022
Guieysse B, Quijano G, Muñoz Torre R (2011) Airlift bioreactors-bioreactors design. Comprehensive Biotechnology
Heidemann R, Mered M, Wang DQ, Gardner B, Zhang C, Michaels J, Konstantinov K (2001) The one step inoculation concept: a new seed-train expansion for recombinant mammalian cell lines. In: Animal cell technology: from target to market. Springer, Dordrecht, pp 449–451
Heidemann R, Mered M, Wang DQ, Gardner B, Zhang C, Michaels J, Konstantinov K (2002) A new seed-train expansion method for recombinant mammalian cell lines. Cytotechnology 38(1):99–108
Ho SC, Bardor M, Feng H, Tong YW, Song Z, Yap MG, Yang Y (2012) IRES-mediated tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell lines. J Biotechnol 157(1):130–139
Indian Pharmaceutical Industry (2022) India Brand Equity Foundation
Global Biopharmaceutical Market (2021–2026) by Product Type, Therapeutic Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis, ID: 5397295 Report May 2021 Region: Global 230 Pages Infogence Global Research
Jenkins N, Curling EM (1994) Glycosylation of recombinant proteins: problems and prospects. Enzyme Microb Technol 16(5):354–364
Kantarci N, Borak F, Ulgen KO (2005) Bubble column reactors. Process Biochem 40(7):2263–2283
Lai T, Yang Y, Ng SK (2013) Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals 6(5):579–603
Lazar ARYE (1991) Immobilization of animal cells in fixed bed bioreactors. Biotechnol Adv 9:411–424
Loganathan S, Athalye SN, Joshi SR (2020) Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther 20(9):1025–1031
Lonial S, Durie B, Palumbo A, San-Miguel J (2016) Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia 30(3):526–535
Maier RM, Pepper IL (2015) Bacterial growth. In: Environmental microbiology. Academic, pp 37–56
Martens S, Borchert SO, Faber BW, Cornelissen G, Luttmann R (2011) Fully automated production of potential Malaria vaccines with Pichia pastoris in integrated processing. Eng Life Sci 11(4):429–435
McKeehan WL, Barnes D, Reid L, Stanbridge E, Murakami H, Sato GH (1990) Frontiers in mammalian cell culture. In Vitro Cell Dev Biol 26:9–23
Mishra RK (2021) CCMB Covid-19 chronicles, 2nd edn
Mordor Intelligence Biopharmaceuticals market—growth, trends, COVID-19 impact, and forecasts (2022–2027). https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-marketindustry. Accessed March 2022
Ng SK, Tan TRM, Wang Y, Ng D, Goh LT, Bardor M, Wong VV, Lam KP (2012) Production of functional soluble Dectin-1 glycoprotein using an IRES-linked destabilized-dihydrofolate reductase expression vector. PLoS One 7(12):e52785
Why PM Modi addressed, India as a pharmacy of the world, Pharmatutor, 2021
Pörtner R, Platas OB, Fassnacht D, Nehring D, Czermak P, Märkl H (2007) Fixed bed reactors for the cultivation of mammalian cells: design, performance and scale-up. Open Biotechnol J 1:41–46
Biopharmaceuticals Market (By Type: Monoclonal Antibodies, Insulin, Vaccine, Hormone, Interferon, Erythropoietin, Growth & Coagulation Factor, and Others; By Application: Blood Disorder, Oncology, Infectious Disease, Neurological Disease, Cardiovascular Disease, Metabolic Disease, Immunology, and Others)—Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021–2030, Precedence Research (2020)
Rafiq QA, Brosnan KM, Coopman K, Nienow AW, Hewitt CJ (2013) Culture of human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. Biotechnol Lett 35(8):1233–1245
Rajmohan KS, Yadav H, Vaishnavi S, Gopinath M, Varjani S (2020) Perspectives on bio-oil recovery from plastic waste. In: Current developments in biotechnology and bioengineering. Elsevier, pp 459–480
Regidor C, Posada M, Monteagudo D, Garauled C, Somolinos N, Forés R, Briz M, Fernández M (1999a) Stem cell transplantation. Exp Hematol 27:380–385
Regidor C, Posada M, Monteagudo D, Garauled C, Somolinos N, Fores R, Briz M, Fernandez M (1999b) Stem cell transplantation. Exp Hematol 27:380–385
Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9):1073–1078
Slivac I, Srček VG, Radošević K, Kmetič I, Kniewald Z (2006) Aujeszky’s disease virus production in disposable bioreactor. J Biosci 31(3):363–368
Cell Culture Market to Expand at CAGR of 6.4% During Forecast Period, Says TMR Study, Transparency Market Research, 2022
Verma A, Verma M, Singh A (2020) Animal tissue culture principles and applications. Animal Biotechnol:269–293. https://doi.org/10.1016/B978-0-12-811710-1.00012-4
Wright B, Bruninghaus M, Vrabel M, Walther J, Shah N, Bae SA, Johnson T, Yin J, Zhou W, Konstantinov K (2015) A novel seed-train process: using high-density cell banking, a disposable bioreactor, and perfusion technologies. Bioprocess Int 13(3):16–25
Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393–1398
Zhong JJ (2011) 2.14—Bioreactor engineering. In: Moo-Young M (ed) Comprehensive biotechnology, 2nd edn, pp 165–177
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Arora, P., Singh, V., Kumar, A. (2023). Mammalian Cell Culture: An Edge to Biopharmaceutical Industry. In: Singh, V., Show, P.L. (eds) Biomanufacturing for Sustainable Production of Biomolecules. Springer, Singapore. https://doi.org/10.1007/978-981-19-7911-8_15
Download citation
DOI: https://doi.org/10.1007/978-981-19-7911-8_15
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-7910-1
Online ISBN: 978-981-19-7911-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)